Hsu and colleagues showed that EphA2-targeted CAR-T cells effectively killed EphA2-expressing OS tumor cells in pre-established, targeted xenografts in immunodeficient mice and were associated with prolonged survival. Here, EPHA2 is linked to neoplasm.